IgA nephropathy currently has no established cure, meaning no treatment is proven to remove the underlying immune process permanently. Instead, clinicians focus on supporting kidney health, slowing disease progression, and addressing factors that influence long-term outcomes.
In scientific literature, “cure” is rarely used for chronic kidney conditions because these diseases often follow long timelines and can behave differently from person to person.
Long-term outcomes in IgAN are highly variable, ranging from stable kidney function for decades to progressive loss of kidney function over time. Studies show that some individuals experience only mild changes, while others may see more significant decline over the course of many years.¹
Key insights from research:
These numbers describe population-level observations — not predictions for any individual.
IgAN varies widely due to several interacting factors:
Research consistently shows that people with preserved kidney function at diagnosis tend to have more stable long-term outcomes.³
Higher proteinuria is associated with faster decline in kidney function in clinical studies.³
Long-term kidney health is closely linked to maintaining healthy blood pressure.⁴
Younger individuals often have a slower initial progression but may still require long-term monitoring.
Research suggests that immune pathways, mucosal immunity, and genetic components may influence disease activity.⁵
Certain medications used to support kidney function, along with regular clinical follow-up, may influence long-term trajectories.⁴
Each of these factors can contribute to unique, individual patterns.
Yes — some people experience periods where urine tests improve significantly or return to normal ranges, often described as clinical remission in research.
Remission does not mean that the underlying immune condition is eliminated; rather, it reflects a phase of lower disease activity.
Studies show:
Modern studies highlight several areas that may influence long-term kidney health. These do not replace clinical care and are not medical advice but summarize common themes in the literature:
Extensive research shows that maintaining healthy blood pressure aligns with better kidney outcomes across chronic kidney diseases, including IgAN.⁴
Therapies that lower protein in the urine are associated with slower decline in kidney function.³
General kidney-healthy habits — such as reducing sodium intake, staying physically active, and avoiding smoking — are frequently discussed in guidelines and may support long-term kidney wellbeing.⁴
In recent years, several new therapies have been approved in different markets, targeting inflammation, mucosal immunity, or the renin–angiotensin system. Research into IgAN is growing rapidly.⁵
Some people with IgAN may eventually develop chronic kidney disease or kidney failure. Studies estimate that up to one-third of patients may progress to advanced stages over 20–30 years.²
However, many remain stable for long periods, and early supportive care often plays an important role.
Importantly, no article can predict individual outcomes. Conversations with a nephrologist are essential for understanding personal kidney trends.
While no lifestyle change can cure IgAN, research highlights several areas that can support overall kidney wellbeing:
These are general strategies, not treatment instructions.
Disclaimer: This article is for educational purposes only. It does not diagnose or treat any medical condition. Patients should consult a qualified nephrologist for individual advice. mama health offers information and support and does not replace a doctor.
1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013.
2. Schena FP. A narrative review on IgA nephropathy: long-term outcomes. Kidney Int.
3. KDIGO Clinical Practice Guideline for Glomerulonephritis (IgAN section).
4. KDIGO Blood Pressure Guideline.
5. Kiryluk K, Novak J. The pathogenesis of IgA nephropathy. Nat Rev Nephrol.
6. Coppo R. Clinical remission and long-term prognosis in IgAN: evidence from cohort studies.
